Vosaroxin

Summary

Vosaroxin (CHEMBL68117) is a phase-3 clinical-stage small-molecule topoisomerase II inhibitor (ATC L01XX53); indicated across 8 conditions including neoplasm and acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01XX53
• Indications: 8 conditions
• Clinical trials: 14
• Chemistry: 401.4 Da · C18H19N5O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL68117
Name	Vosaroxin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9952884
ChEBI	CHEBI:231651
ATC	L01XX53
Molecular formula	C18H19N5O4S
Molecular weight	401.4
InChIKey	XZAFZXJXZHRNAQ-STQMWFEESA-N

SMILES: CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O

IUPAC name: 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid

ChEBI definition: A 1,8-naphthyridine derivative that is 1,8-naphthyridin-4(1H)-one substituted by 1,3-thiazol-2-yl, carboxy, and (3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl groups at positions 1, 3, and 7, respectively. It targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to apoptosis in cancer cells.

Pharmacological roles (ChEBI): topoisomerase II inhibitor, antineoplastic agent, intercalator, apoptosis inducer, radiosensitizing agent.

Also known as: AG-7352, SNS-595, SPC-595, Vosaroxin, Vosaroxina, Vosaroxine, VOSAROXIN, Voreloxin (Hydrochloride)

Parent form; salt/anhydrous children: CHEMBL543336

Patent coverage: 274 distinct patent families (777 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
acute lymphoblastic leukemia	1	MONDO:0004967	EFO:0000220
chronic myeloid leukemia	1	MONDO:0011996	EFO:0000339
leukemia	1	MONDO:0005059	EFO:0000565

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1	4
PHASE1/PHASE2	2
PHASE3	1
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02416388	PHASE2/PHASE3	RECRUITING	Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
NCT01191801	PHASE3	COMPLETED	Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
NCT00252382	PHASE2	COMPLETED	Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
NCT00298896	PHASE2	COMPLETED	Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
NCT00607997	PHASE2	COMPLETED	Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
NCT01893320	PHASE1/PHASE2	COMPLETED	Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
NCT01980056	PHASE1/PHASE2	COMPLETED	Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
NCT02658487	PHASE2	COMPLETED	Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
NCT03338348	PHASE2	COMPLETED	Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
NCT00091585	PHASE1	COMPLETED	Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
NCT00094159	PHASE1	COMPLETED	Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
NCT00246662	PHASE1	COMPLETED	Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
NCT01913951	PHASE1	COMPLETED	Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
NCT02485353	Not specified	TERMINATED	Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).